Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.

BACKGROUND Type 1 diabetes mellitus (T1DM) is an autoimmune disorder of unknown etiology. It has been suggested that metalloproteinases (MMPs) play important roles in the development and complications of autoimmune disorders. This article presents our research on the expression or activities of MMPs in Taiwanese T1DM patients. METHODS Levels and activities of plasma MMP-2 and MMP-9 in patients with T1DM were investigated and compared to those of control individuals by enzyme-linked immunosorbent assay and zymography. RESULTS Circulatory levels and activities of MMP-2 and MMP-9 in patients with T1DM were significantly higher than those in control subjects. CONCLUSIONS MMP expression and activities are significantly increased in patients with T1DM. Our results not only document plasma MMPs levels and activities in the Taiwanese population (with a very low type 1 diabetic incidence), but also suggest that MMP expression and activity are elevated before the onset of complications in diabetic patients.

[1]  M. Lan,et al.  Autoantibodies against IA-2, GAD, and topoisomerase II in type 1 diabetic patients. , 2004, Biochemical and biophysical research communications.

[2]  F. Mannello,et al.  Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. , 2003, Clinical chemistry.

[3]  S. Tyagi,et al.  Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice , 2003, Diabetologia.

[4]  A. Ergul,et al.  Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. , 2002, Diabetes.

[5]  S. Chandran,et al.  Peripheral blood level alterations of TIMP‐1, MMP‐2 and MMP‐9 in patients with Type 1 diabetes , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[6]  Z. Ao,et al.  Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. , 2001, American journal of physiology. Renal physiology.

[7]  J. Verheijen,et al.  Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[8]  H. Mabuchi,et al.  Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis , 2001, Clinical chemistry and laboratory medicine.

[9]  T. Tai,et al.  Genetic epidemiology of type 1 diabetes mellitus in Taiwan. , 2000, Diabetes research and clinical practice.

[10]  S. Halimi,et al.  Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. , 2000, Diabetes & metabolism.

[11]  J. Hwang,et al.  Relationship between autoantibodies against glutamic acid decarboxylase, thyroglobulin/thyroid microsome and DNA topoisomerase II in the clinical manifestation of patients with type 1 diabetes mellitus in Taiwan. , 2000, European journal of endocrinology.

[12]  Marti Hp.  [Role of matrix metalloproteinases in the progression of renal lesions]. , 2000, Presse medicale.

[13]  T. Nakamura,et al.  Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  S. Loening,et al.  Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. , 1998, Clinical chemistry.

[15]  G. Gambaro,et al.  Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM , 1997, Diabetologia.